SynthesisReviews in cardiovascular medicine2026
Gender-Specific Associations Between Sex Hormones and Cardiovascular Disease: A Systematic Review and Meta-Analysis.
Synthesis in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sex hormones play a critical role in the development of cardiovascular disease (CVD); however, the associations between specific circulating sex hormones and cardiovascular outcomes differ by sex, and the evidence remains inconclusive. Methods: A systematic review and meta-analysis of 23 prospective cohort studies was conducted to examine the associations between sex hormones and cardiovascular outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted, and random- or fixed-effects models were applied based on heterogeneity. Subgroup analyses were performed by hormone type, age, and sex. Results: In men, higher total testosterone (TT) levels were associated with a reduced risk of CVD. No consistent associations were found between sex hormone-binding globulin (SHBG), calculated free testosterone (cFT), and estradiol with CVD. In women, elevated TT and cFT were linked to increased CVD risk. Estradiol exhibited a modest and uncertain protective effect. An outcome-specific analysis revealed that higher dehydroepiandrosterone (DHEA) levels were linked to an increased risk of heart failure, while SHBG was associated with reduced cardiovascular mortality. Conversely, higher estradiol concentrations correlated with increased cardiovascular mortality. Conclusions: Sex hormones exert complex, sex-specific, and outcome-dependent effects on cardiovascular risk. In men, higher testosterone levels are associated with lower overall CVD risk, whereas in women, these levels are linked to higher CVD and heart failure risk. Estradiol demonstrated a protective trend against major adverse cardiovascular events (MACEs), yet was linked to increased cardiovascular mortality. Higher SHBG levels are associated with lower cardiovascular mortality, whereas higher DHEA levels correlate with increased heart failure risk. Together, these findings underscore the importance of integrating sex, age, and endocrine context into cardiovascular risk stratification and prevention strategies. The PROSPERO Registration: CRD42024551055, Registration Link: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024551055.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.